Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
治疗和预防肺淋巴管平滑肌瘤病 (LAM) 和结节性硬化症 (TSC) 的新型联合疗法
基本信息
- 批准号:10697901
- 负责人:
- 金额:$ 30万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAdverse eventAffectAgeAnimalsAntibodiesBenignBiological ProductsBrainBronchoalveolar LavageC57BL/6 MouseCancer ModelCategoriesCell CountCell Culture TechniquesCell LineCellsClinicClinicalCodeCombined Modality TherapyComplexControl GroupsCystCytoplasmDataDevelopmentDisadvantagedDiseaseDoseEnsureEnvironmentEyeFDA approvedFRAP1 geneFemale of child bearing ageFibroblastsFlow CytometryGeneticGenetic DiseasesGoalsGrantGrowthHeartHumanImmuneImmune EvasionImmunocompetentImmunoglobulinsImmunohistochemistryImmunologic SurveillanceImmunosuppressionImmunosuppressive AgentsImmunotherapyIn VitroIncubatedInheritedInjectionsInvestigationKidneyLaboratoriesLesionLibrariesLifeLiteratureLungLung LymphangioleiomyomatosisLung TransplantationLung diseasesLymphangioleiomyomatosisLymphatic ObstructionMalignant NeoplasmsMedicalMesenchymalModelingMorphologyMusMutationNeoplasmsNoduleOrganPD-1 blockadePathway interactionsPatientsPatternPennsylvaniaPersonsPharmaceutical PreparationsPneumothoraxPregnancyPreparationPreventionPreventive treatmentProliferatingPropertyPublishingQuantitative Reverse Transcriptase PCRRare DiseasesRecurrenceRegimenReportingResearchSafetySequential TreatmentShortness of BreathSignal TransductionSirolimusSkinSmooth Muscle MyocytesStructureSurfaceSuspensionsSystemTSC1 geneTSC1/2 geneTSC2 geneTailTestingTherapeuticTissuesTranslatingTransplant RecipientsTuberous SclerosisTumor Suppressor GenesUnited StatesUniversitiesUp-RegulationVeinsWestern BlottingWomanWorkanti-PD-1anti-PD1 antibodiesanti-PD1 therapycheckpoint inhibitionchild bearingclinical developmentclinical translationcomparison groupcurative treatmentsefficacy evaluationexperimental studygene functionimmune checkpoint blockadeimmunoregulationimprovedimproved outcomein vivointraperitoneallung lesionmTOR Inhibitormouse modelmutantneoplasticnovelnovel therapeuticspembrolizumabprogrammed cell death ligand 1standard of caretime usetumor
项目摘要
1 ABSTRACT
2 Tuberous sclerosis (TS), also called tuberous sclerosis complex, is a rare, multi-systemic genetic and often life-
3 threatening disease that causes benign tumors to grow in the brain and on other vital organs such as the kidneys,
4 heart, eyes, lungs, and skin. Lymphangioleiomyomatosis (LAM) is a TS-related tumor-like disorder. Both occur
5 as a consequence of an inherited or sporadic mutation in either the TSC1 or TSC2 gene, which function as
6 negative regulators of the mTOR pathway. Uncontrolled mTORC1 activity leads to the neoplastic proliferation of
7 abnormal smooth muscle cells (LAM cells) in the lungs, progressive shortness of breath, recurrent
8 pneumothoraxes, and loss of pulmonary tissue structure and function. In addition, published data suggests that
9 LAM cells may evade immune surveillance by upregulating the surface expression of programmed death-ligand 1
10 (PD-L1). LAM is a rare disease affecting women in childbearing age. The first and only FDA-approved treatment
11 for LAM is the immunosuppressant Rapamycin. It is the current standard-of-care and acts by inhibiting mTORC1.
12 Rapamycin has several clinical disadvantages, including a considerable number of non-responders, severe
13 adverse events due to its immunosuppressive properties and pregnancy category C, limiting its use in women of
14 childbearing age. Thus, there is a high unmet medical need to develop alternative and safer treatment options for
15 LAM and TS. We have identified Anti-PD1 checkpoint blockade as a potential novel therapy for LAM/TS. Using
16 our recently developed immunocompetent mouse model, the Co-PI Prof. Krymskaya was able to show that
17 treatment with an Anti-PD1 antibody significantly improved mouse surival. To advance immunetherapy for LAM,
18 our goal for this grant is the investigation of the mechanistic interplay between Rapamyin and Anti-PD1 antibodies
19 to harness the potential of a combination therapy in vitro and in vivo. Aim 1 will cover a set of in vitro studies,
20 investigating immune-relevant expression patterns and underlying cellular effects on mTOR and related signaling
21 pathways, since the relationship between the former and checkpoint blockade is not fully understood yet. We will
22 use immortalized TSC2-null 101, 102 and TSC2-expressing 103 cells before moving on to our expanded library
23 of primary human LAM-derived AML (LAMD) cells, originating from over 25 LAM patients. Investigating the effect
24 of Rapamycin and mTOR/Akt signalling will increase our understanding of the connection between those pathways
25 and PD-L1 upregulation, before moving on to Aim 2. The in vivo proof of concept will compare preventative and
26 therapeutic co-treatment with Anti-PD1 and Rapamying in an immunocompetent TSC2-null murine model
27 developed at the laboratory of Prof. Krymskaya at the University of Pennsylvania. We will evaluate prevention of
28 TSC2-null lesion growth, immunohistochemical and lung morphology changes and animal survival. This project
29 aims to develop a novel therapy for patients with the devastating diseases of LAM/TS. Based on Pembrolizumab’s
30 favorable safety profile in its approved indications, positive efficacy results in our studies would enable an
31 accelerated clinical development under FDA BPIC act for biologics and orphan disease designation for LAM/TS.
32
1篇摘要
2结节性硬化症(TS),也称为结节性硬化症,是一种罕见的,多系统遗传性,往往是终身的,
3威胁性疾病,导致良性肿瘤生长在大脑和其他重要器官,如肾脏,
4心脏、眼睛、肺和皮肤。淋巴管平滑肌瘤病(LAM)是一种与TS相关的肿瘤样疾病。均发生
5是由于TSC 1或TSC 2基因中的遗传性或散发性突变,其功能是
mTOR通路的6个负调节因子。不受控制的mTORC 1活性导致肿瘤性增殖,
7例肺部平滑肌细胞(LAM细胞)异常,进行性呼吸短促,复发
8例气胸,肺组织结构和功能丧失。此外,公布的数据表明,
LAM细胞可能通过上调程序性死亡配体1的表面表达来逃避免疫监视。
10(PD-L1)。LAM是一种影响育龄女性的罕见疾病。第一个也是唯一一个FDA批准的治疗方法
11对于LAM是免疫抑制剂雷帕霉素。它是目前的标准治疗,通过抑制mTORC 1发挥作用。
12雷帕霉素有几个临床缺点,包括相当数量的无应答者,严重的
由于其免疫抑制特性和妊娠C类,13起不良事件,限制了其在以下女性中的使用:
14生育年龄因此,开发替代和更安全的治疗选择是高度未满足的医疗需求,
15、我和你我们已经确定抗PD 1检查点阻断作为LAM/TS的潜在新疗法。使用
16我们最近开发的免疫活性小鼠模型,Co-PI Krymskaya教授能够证明,
17用抗PD 1抗体治疗显著改善小鼠存活。为了推进LAM的免疫治疗,
我们的目标是研究Rapamyin和抗PD 1抗体之间的相互作用机制。
19利用体外和体内联合治疗的潜力。目标1将涵盖一系列体外研究,
20研究免疫相关的表达模式和对mTOR和相关信号传导的潜在细胞效应
21条途径,因为前者与检查站封锁之间的关系尚未完全了解。我们将
22使用无限增殖的TSC 2-null 101、102和表达TSC 2的103细胞,然后转移到我们的扩增文库
23个原代人LAM衍生的AML(LAMD)细胞,来源于超过25个LAM患者。调查影响
24雷帕霉素和mTOR/Akt信号传导将增加我们对这些途径之间联系的理解
25和PD-L1上调,然后转移到目标2。体内概念验证将比较预防性和
26在免疫活性TSC 2缺失鼠模型中用抗PD 1和Rapamying的治疗性共同治疗
27在宾夕法尼亚大学Krymskaya教授的实验室开发的。我们将评估预防
28 TSC 2-null病灶生长、免疫组织化学和肺形态学变化及动物存活率。这个项目
29旨在为患有LAM/TS的毁灭性疾病的患者开发一种新的疗法。基于Pembrolizumab的
在其批准的适应症中有30个有利的安全性特征,我们的研究中的积极疗效结果将使
31根据FDA BPIC法案加速LAM/TS生物制剂和孤儿病认定的临床开发。
32
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VERA P KRYMSKAYA其他文献
VERA P KRYMSKAYA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VERA P KRYMSKAYA', 18)}}的其他基金
Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis
硝唑尼特作为罕见疾病淋巴管平滑肌瘤病和结节性硬化症的新疗法
- 批准号:
10258194 - 财政年份:2021
- 资助金额:
$ 30万 - 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
- 批准号:
10394731 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
- 批准号:
10163904 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
mTOR signaling in lung homeostasis, aging and disease
mTOR 信号在肺稳态、衰老和疾病中的作用
- 批准号:
10609457 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别:
Urokinase-type plasminogen activator (uPA) in pathogenesis of lymphangioleiomyomatosis (LAM)
尿激酶型纤溶酶原激活剂 (uPA) 在淋巴管平滑肌瘤病 (LAM) 发病机制中的作用
- 批准号:
10323035 - 财政年份:2019
- 资助金额:
$ 30万 - 项目类别:
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)
肺淋巴管平滑肌瘤病 (LAM) 中的淋巴管生成
- 批准号:
9242060 - 财政年份:2016
- 资助金额:
$ 30万 - 项目类别:
Lymphangiogenesis in Pulmonary Lymphangioleiomyomatosis (LAM)
肺淋巴管平滑肌瘤病 (LAM) 中的淋巴管生成
- 批准号:
9078976 - 财政年份:2016
- 资助金额:
$ 30万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 30万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 30万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 30万 - 项目类别: